{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:21:54Z","timestamp":1793830914228,"version":"4.6.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Fakult\u00e4t Heidelberg der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cisplatin (CDDP)-containing hyperthermic intraperitoneal chemotherapy (HIPEC) is frequently applied in selected patients with peritoneal malignancies derived from ovarian cancer, gastric cancer, and primary peritoneal mesothelioma. HIPEC with CDDP increases perioperative morbidity, in particular by inducing acute kidney injury (AKI). Factors contributing to occurrence of AKI after intraperitoneal perfusion with CDDP have not been sufficiently evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and Methods<\/jats:title>\n                <jats:p>Data from 63 patients treated with a CDDP-containing HIPEC regimen were retrospectively analyzed concerning demographics, underlying disease, surgery, and HIPEC details to evaluate risk factors of AKI. A preclinical rat perfusion model was applied to assess the influence of temperature, concentration, perfusate volume, perfusion flow rate, and extent of peritonectomy on drug absorption upon intraperitoneal CDDP perfusion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>AKI occurred in 66.1% of patients undergoing CDDP-containing HIPEC, with total intraoperative fluid influx being a negative and the extent of parietal peritonectomy being a positive independent predictor of postoperative AKI. In a preclinical model, bilateral anterior parietal peritonectomy significantly increased systemic CDDP absorption by 1.6 to 2-fold. CDDP plasma levels in animals were significantly higher after both perfusion with increased CDDP perfusate concentrations and bilateral anterior parietal peritonectomy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>CDDP-containing HIPEC is associated with relevant morbidity owing to its systemic toxicity. Extent of parietal peritonectomy is an independent predictor of AKI. CDDP dose reduction should be considered in case of extensive parietal peritonectomy. Cytostatic drug concentrations in HIPEC perfusate should be paid more attention to than total dose per body surface area. Further clinical studies are needed to confirm the presented preclinical findings.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-022-12661-3","type":"journal-article","created":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T19:03:39Z","timestamp":1670699019000},"page":"2646-2656","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Extensive Peritonectomy is an Independent Risk Factor for Cisplatin HIPEC-Induced Acute Kidney Injury"],"prefix":"10.1245","volume":"30","author":[{"given":"Lukas F.","family":"Liesenfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Quiring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Al-Saeedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Nusshag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus W.","family":"B\u00fcchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,10]]},"reference":[{"key":"12661_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/978-3-319-16205-8_11","volume-title":"Current controversies in cancer care for the surgeon","author":"ML Bryan","year":"2016","unstructured":"Bryan ML, Ahmed S, Votanopoulos KI, Shen P, Levine EA, Stewart JH. Peritoneal carcinomatosis. In: KA Morgan, editor. Current controversies in cancer care for the surgeon. Cham: Springer International Publishing; 2016. p. 185\u2013205. https:\/\/doi.org\/10.1007\/978-3-319-16205-8_11."},{"issue":"1","key":"12661_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3978\/j.issn.2078-6891.2015.106","volume":"7","author":"MG Neuwirth","year":"2016","unstructured":"Neuwirth MG, Alexander HR, Karakousis GC. Then and now: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective. J Gastrointest Oncol. 2016;7(1):18\u201328. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2015.106.","journal-title":"J Gastrointest Oncol"},{"key":"12661_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-4-17","author":"TD Yan","year":"2006","unstructured":"Yan TD, Stuart OA, Yoo D, Sugarbaker PH. Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy. J Transl Med. 2006. https:\/\/doi.org\/10.1186\/1479-5876-4-17.","journal-title":"J Transl Med"},{"issue":"11","key":"12661_CR4","doi-asserted-by":"publisher","first-page":"236","DOI":"10.21037\/atm.2017.03.96","volume":"5","author":"J Kim","year":"2017","unstructured":"Kim J, Bhagwandin S, Labow DM. Malignant peritoneal mesothelioma: a review. Ann Transl Med. 2017;5(11):236\u2013236. https:\/\/doi.org\/10.21037\/atm.2017.03.96.","journal-title":"Ann Transl Med"},{"key":"12661_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708618","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. NEJM. 2018. https:\/\/doi.org\/10.1056\/NEJMoa1708618.","journal-title":"NEJM"},{"issue":"3","key":"12661_CR6","doi-asserted-by":"publisher","first-page":"572","DOI":"10.21037\/jgo.2017.03.11","volume":"8","author":"P Fugazzola","year":"2017","unstructured":"Fugazzola P, Coccolini F, Montori G, et al. Overall and disease-free survival in patients treated with CRS + HIPEC with cisplatin and paclitaxel for gastric cancer with peritoneal carcinomatosis. J Gastrointest Oncol. 2017;8(3):572\u201382. https:\/\/doi.org\/10.21037\/jgo.2017.03.11.","journal-title":"J Gastrointest Oncol"},{"key":"12661_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30599-4","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021. https:\/\/doi.org\/10.1016\/S1470-2045(20)30599-4.","journal-title":"Lancet Oncol"},{"issue":"6","key":"12661_CR8","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1080\/02656736.2017.1293304","volume":"33","author":"EIL Sin","year":"2017","unstructured":"Sin EIL, Chia CS, Tan GHC, Soo KC, Teo MCC. Acute kidney injury in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. Int J Hyperth. 2017;33(6):690\u20135. https:\/\/doi.org\/10.1080\/02656736.2017.1293304.","journal-title":"Int J Hyperth"},{"issue":"1","key":"12661_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00423-014-1253-z","volume":"400","author":"M Desantis","year":"2015","unstructured":"Desantis M, Bernard JL, Casanova V, et al. Morbidity, mortality, and oncological outcomes of 401 consecutive cytoreductive procedures with hyperthermic intraperitoneal chemotherapy (HIPEC). Langenbeck\u2019s Arch Surg. 2015;400(1):37\u20138. https:\/\/doi.org\/10.1007\/s00423-014-1253-z.","journal-title":"Langenbeck\u2019s Arch Surg"},{"issue":"4","key":"12661_CR10","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1245\/s10434-012-2853-x","volume":"20","author":"AE Canda","year":"2013","unstructured":"Canda AE, Sokmen S, Terzi C, et al. Complications and toxicities after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20(4):1082\u20137. https:\/\/doi.org\/10.1245\/s10434-012-2853-x.","journal-title":"Ann Surg Oncol"},{"issue":"29","key":"12661_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1245\/s10434-021-10376-5","volume":"2022","author":"LF Liesenfeld","year":"2022","unstructured":"Liesenfeld LF, Wagner B, Hillebrecht HC, et al. HIPEC-induced acute kidney injury: a retrospective clinical study and preclinical model. Ann Surg Oncol. 2022;2022(29):139\u201351. https:\/\/doi.org\/10.1245\/s10434-021-10376-5.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"12661_CR12","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1136\/ijgc-2018-000099","volume":"29","author":"MA Angeles","year":"2019","unstructured":"Angeles MA, Quenet F, Vieille P, et al. Predictive risk factors of acute kidney injury after cytoreductive surgery and cisplatin-based hyperthermic intra-peritoneal chemotherapy for ovarian peritoneal carcinomatosis. Int J Gynecol Cancer. 2019;29(2):382\u201391. https:\/\/doi.org\/10.1136\/ijgc-2018-000099.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"12661_CR13","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/cam4.80","volume":"2","author":"M Haslinger","year":"2013","unstructured":"Haslinger M, Francescutti V, Attwood K, et al. A contemporary analysis of morbidity and outcomes in cytoreduction\/hyperthermic intraperitoneal chemoperfusion. Cancer Med. 2013;2(3):334\u201342. https:\/\/doi.org\/10.1002\/cam4.80.","journal-title":"Cancer Med"},{"issue":"6","key":"12661_CR14","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.ejso.2015.08.174","volume":"42","author":"M Ceresoli","year":"2016","unstructured":"Ceresoli M, Coccolini F, Ansaloni L. HIPEC and nephrotoxicity: A cisplatin induced effect? EJSO. 2016;42(6):909\u201310. https:\/\/doi.org\/10.1016\/j.ejso.2015.08.174.","journal-title":"EJSO"},{"key":"12661_CR15","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/bjc.2014.602","volume":"112","author":"L Ansaloni","year":"2015","unstructured":"Ansaloni L, Coccolini F, Morosi L, et al. Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. Br J Cancer. 2015;112:306\u201312. https:\/\/doi.org\/10.1038\/bjc.2014.602.","journal-title":"Br J Cancer"},{"key":"12661_CR16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.amsu.2018.09.036","volume":"35","author":"SA Naffouje","year":"2018","unstructured":"Naffouje SA, Tulla KA, Chorley R, Armstrong N, Salti GI. Acute kidney injury increases the rate of major morbidities in cytoreductive surgery and HIPEC. Ann Med Surg. 2018;35:163\u20138. https:\/\/doi.org\/10.1016\/j.amsu.2018.09.036.","journal-title":"Ann Med Surg"},{"issue":"8","key":"12661_CR17","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1245\/ASO.2003.01.018","volume":"10","author":"O Glehen","year":"2003","unstructured":"Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10(8):863\u20139. https:\/\/doi.org\/10.1245\/ASO.2003.01.018.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"12661_CR18","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1245\/s10434-007-9429-1","volume":"14","author":"S Kusamura","year":"2007","unstructured":"Kusamura S, Baratti D, Younan R, et al. Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity. Ann Surg Oncol. 2007;14(9):2550\u20138. https:\/\/doi.org\/10.1245\/s10434-007-9429-1.","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"12661_CR19","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.3109\/0886022X.2014.949758","volume":"36","author":"HA Hakeam","year":"2014","unstructured":"Hakeam HA, Breakiet M, Azzam A, Nadeem A, Amin T. The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery. Ren Fail. 2014;36(10):1486\u201391. https:\/\/doi.org\/10.3109\/0886022X.2014.949758.","journal-title":"Ren Fail"},{"issue":"2","key":"12661_CR20","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ejso.2015.07.016","volume":"42","author":"N Bouhadjari","year":"2016","unstructured":"Bouhadjari N, Gabato W, Calabrese D, Msika S, Keita H. Hyperthermic intraperitoneal chemotherapy with cisplatin: amifostine prevents acute severe renal impairment. EJSO. 2016;42(2):219\u201323. https:\/\/doi.org\/10.1016\/j.ejso.2015.07.016.","journal-title":"EJSO"},{"issue":"3","key":"12661_CR21","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00280-007-0484-x","volume":"61","author":"B Royer","year":"2008","unstructured":"Royer B, Delroeux D, Guardiola E, et al. Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer. Cancer Chemother Pharmacol. 2008;61(3):415\u201321. https:\/\/doi.org\/10.1007\/s00280-007-0484-x.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"12661_CR22","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1055\/s-2005-916280","volume":"18","author":"PH Sugarbaker","year":"2005","unstructured":"Sugarbaker PH. Surgical management of carcinomatosis from colorectal cancer. Clin Colon Rectal Surg. 2005;18(3):190\u2013203. https:\/\/doi.org\/10.1055\/s-2005-916280.","journal-title":"Clin Colon Rectal Surg"},{"issue":"12","key":"12661_CR23","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1093\/ndt\/gfs375","volume":"27","author":"D Fliser","year":"2012","unstructured":"Fliser D, Laville M, Covic A, et al. A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant. 2012;27(12):4263\u201372. https:\/\/doi.org\/10.1093\/ndt\/gfs375.","journal-title":"Nephrol Dial Transplant"},{"key":"12661_CR24","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jss.2020.03.067","volume":"253","author":"LF Liesenfeld","year":"2020","unstructured":"Liesenfeld LF, Hillebrecht HC, Klose J, Schmidt T, Schneider M. Impact of perfusate concentration on HIPEC efficacy and toxicity in a rodent model. J Surg Res. 2020;253:262\u201371. https:\/\/doi.org\/10.1016\/j.jss.2020.03.067.","journal-title":"J Surg Res"},{"issue":"1","key":"12661_CR25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1258\/la.2011.011021","volume":"46","author":"E Gouma","year":"2012","unstructured":"Gouma E, Simos Y, Verginadis I, Lykoudis E, Evangelou A, Karkabounas S. A simple procedure for estimation of total body surface area and determination of a new value of Meeh\u2019s constant in rats. Lab Anim. 2012;46(1):40\u20135. https:\/\/doi.org\/10.1258\/la.2011.011021.","journal-title":"Lab Anim"},{"issue":"1","key":"12661_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3978\/j.issn.2078-6891.2015.105","volume":"7","author":"P Sugarbaker","year":"2016","unstructured":"Sugarbaker P, van der Speeten K. Surgical technology and pharmacology of HIPEC. J Gastrointest Oncol. 2016;7(1):29\u201344. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2015.105.","journal-title":"J Gastrointest Oncol"},{"key":"12661_CR27","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3390\/jcm7120567","volume":"7","author":"C Yurttas","year":"2018","unstructured":"Yurttas C, Hoffmann G, Tolios A, et al. Systematic review of variations in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal cancer. J Clin Med. 2018;7:567. https:\/\/doi.org\/10.3390\/jcm7120567.","journal-title":"J Clin Med"},{"issue":"5","key":"12661_CR28","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1080\/02656736.2017.1291999","volume":"33","author":"L Lemoine","year":"2017","unstructured":"Lemoine L, Sugarbaker P, Van der Speeten K. Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma. Int J Hyperth. 2017;33(5):582\u201392. https:\/\/doi.org\/10.1080\/02656736.2017.1291999.","journal-title":"Int J Hyperth"},{"issue":"11","key":"12661_CR29","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/bjc.1998.710","volume":"78","author":"K Aabo","year":"1998","unstructured":"Aabo K, Adams M, Adnitt P, et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Br J Cancer. 1998;78(11):1479\u201387. https:\/\/doi.org\/10.1038\/bjc.1998.710.","journal-title":"Br J Cancer"},{"issue":"2","key":"12661_CR30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3747\/co.v18i2.663","volume":"18","author":"F Mohamed","year":"2011","unstructured":"Mohamed F, Cecil T, Moran B, Sugarbaker P. A new standard of care for the management of peritoneal surface malignancy. Curr Oncol. 2011;18(2):84\u201396. https:\/\/doi.org\/10.3747\/co.v18i2.663.","journal-title":"Curr Oncol"},{"issue":"1","key":"12661_CR31","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s00268-009-0281-2","volume":"34","author":"AG Kerscher","year":"2010","unstructured":"Kerscher AG, Mallalieu J, Pitroff A, Kerscher F, Esquivel J. Morbidity and mortality of 109 consecutive cytoreductive procedures with hyperthermic intraperitoneal chemotherapy (HIPEC) performed at a community hospital. World J Surg. 2010;34(1):62\u20139. https:\/\/doi.org\/10.1007\/s00268-009-0281-2.","journal-title":"World J Surg"},{"issue":"3","key":"12661_CR32","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.suronc.2018.05.025","volume":"27","author":"J Ye","year":"2018","unstructured":"Ye J, Ren Y, Wei Z, et al. Nephrotoxicity and long-term survival investigations for patients with peritoneal carcinomatosis using hyperthermic intraperitoneal chemotherapy with cisplatin: a retrospective cohort study. Surg Oncol. 2018;27(3):456\u201361. https:\/\/doi.org\/10.1016\/j.suronc.2018.05.025.","journal-title":"Surg Oncol"},{"key":"12661_CR33","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s11605-015-2743-1","volume":"19","author":"L Colantonio","year":"2015","unstructured":"Colantonio L, Claroni C, Fabrizi L, et al. A randomized trial of goal directed vs standard fluid therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Gastrointest Surg. 2015;19:722\u20139. https:\/\/doi.org\/10.1007\/s11605-015-2743-1.","journal-title":"J Gastrointest Surg"},{"issue":"4","key":"12661_CR34","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s12094-018-1944-y","volume":"21","author":"N Esteve-P\u00e9rez","year":"2019","unstructured":"Esteve-P\u00e9rez N, Ferrer-Robles A, G\u00f3mez-Romero G, et al. Goal-directed therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a prospective observational study. Clin Transl Oncol. 2019;21(4):451\u20138. https:\/\/doi.org\/10.1007\/s12094-018-1944-y.","journal-title":"Clin Transl Oncol"},{"key":"12661_CR35","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00280-005-0074-8","volume":"57","author":"PH Sugarbaker","year":"2006","unstructured":"Sugarbaker PH, Anthony AO, Carmignani SCP. Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol. 2006;57:703\u20138. https:\/\/doi.org\/10.1007\/s00280-005-0074-8.","journal-title":"Cancer Chemother Pharmacol"},{"key":"12661_CR36","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1245\/s10434-012-2790-8","volume":"20","author":"JC Leinwand","year":"2013","unstructured":"Leinwand JC, Bates GE, Allendorf JD, Chabot JA, Lewin SN, Taub RN. Body surface area predicts plasma oxaliplatin and pharmacokinetic advantage in hyperthermic intraoperative intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20:1101\u20134. https:\/\/doi.org\/10.1245\/s10434-012-2790-8.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"12661_CR37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/bcp.13773","volume":"85","author":"LAW de Jong","year":"2019","unstructured":"de Jong LAW, Elekonawo FMK, de Reuver PR, et al. Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure. Br J Clin Pharmacol. 2019;85(1):47\u201358. https:\/\/doi.org\/10.1111\/bcp.13773.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"12661_CR38","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1245\/s10434-021-10508-x","volume":"29","author":"A Kurreck","year":"2022","unstructured":"Kurreck A, Gronau F, Alberto Vilchez ME, et al. Sodium thiosulfate reduces acute kidney injury in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with cisplatin: a single-center observational study. Ann Surg Oncol. 2022;29(1):152\u201362. https:\/\/doi.org\/10.1245\/s10434-021-10508-x.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"12661_CR39","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/02656736.2020.1795277","volume":"37","author":"N Laplace","year":"2020","unstructured":"Laplace N, Kepenekian V, Friggeri A, et al. Sodium thiosulfate protects from renal impairement following hyperthermic intraperitoneal chemotherapy (HIPEC) with Cisplatin. Int J Hyperth. 2020;37(1):897\u2013902. https:\/\/doi.org\/10.1080\/02656736.2020.1795277.","journal-title":"Int J Hyperth"},{"issue":"2","key":"12661_CR40","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000011847","volume":"55","author":"P Jacquet","year":"1998","unstructured":"Jacquet P, Averbach A, Stephens AD, Anthony Stuart O, Chang D, Sugarbaker PH. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology. 1998;55(2):130\u20138. https:\/\/doi.org\/10.1159\/000011847.","journal-title":"Oncology"},{"issue":"2","key":"12661_CR41","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s00280-003-0626-8","volume":"52","author":"VV De Lima","year":"2003","unstructured":"De Lima VV, Stuart OA, Mohamed F, Sugarbaker PH. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. Cancer Chemother Pharmacol. 2003;52(2):108\u201312. https:\/\/doi.org\/10.1007\/s00280-003-0626-8.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"12661_CR42","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ejso.2011.04.007","volume":"37","author":"PH Sugarbaker","year":"2011","unstructured":"Sugarbaker PH, Van der Speeten K, Anthony Stuart O, Chang D. Impact of surgical and clinical factors on the pharmacology of intraperitoneal doxorubicin in 145 patients with peritoneal carcinomatosis. EJSO. 2011;37(8):719\u201326. https:\/\/doi.org\/10.1016\/j.ejso.2011.04.007.","journal-title":"EJSO"},{"issue":"14","key":"12661_CR43","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.18632\/oncotarget.26667","volume":"10","author":"L Lemoine","year":"2019","unstructured":"Lemoine L, Thijssen E, Carleer R, et al. Body surface area-based versus concentration-based intraperitoneal perioperative chemotherapy in a rat model of colorectal peritoneal surface malignancy: pharmacologic guidance towards standardization. Oncotarget. 2019;10(14):1407\u201324. https:\/\/doi.org\/10.18632\/oncotarget.26667.","journal-title":"Oncotarget"},{"issue":"9","key":"12661_CR44","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1097\/01.cad.0000176505.94175.d4","volume":"16","author":"B Royer","year":"2005","unstructured":"Royer B, Guardiola E, Polycarpe E, et al. Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding. Anti-Cancer Drugs. 2005;16(9):1009\u201316. https:\/\/doi.org\/10.1097\/01.cad.0000176505.94175.d4.","journal-title":"Anti-Cancer Drugs"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12661-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-12661-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12661-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T14:04:51Z","timestamp":1681135491000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-12661-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,10]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["12661"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-12661-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,10]]},"assertion":[{"value":"10 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L. F. L., E. Q., M. A., C. N., M. W. B., and M. S. report neither any disclosure nor any financial support.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}